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Introduction
Metformin is now standard ﬁrst-line treatment (in
addition to lifestyle modiﬁcations) for type 2 diabe-
tes (T2D) (1). The progressive nature of T2D,
including declining beta-cell function, usually neces-
sitates addition of other antihyperglycaemic agents to
metformin, as blood glucose levels rise. However,
current guidelines vary with respect to second-line
therapy (1,2). A meta-analysis of currently available
non-insulin antihyperglycaemic agents added to met-
formin revealed that, while reductions in glycosylated
haemoglobin (HbA1c) were similar across several
drug classes (including sulphonylureas, thiazolinedi-
ones and alpha-glucosidase inhibitors; reduction
range: 0.64–0.97%), treatment side effects (such as
weight gain and⁄or hypoglycaemia) varied consider-
ably (3). Therefore, head-to-head studies of glucose-
lowering agents are needed to compare overall
clinical efﬁcacy and safety when added to metformin.
Treatment intensiﬁcation with incretin-based ther-
apies is appealing given that they provide good gly-
caemic control with a low risk of hypoglycaemia,
because of the glucose-dependent stimulation of
SUMMARY
Aim: The aim of this study was to compare the efﬁcacy and safety of once-daily
human glucagon-like peptide-1 analogue liraglutide with dipeptidyl peptidase-4
inhibitor sitagliptin, each added to metformin, over 52 weeks in individuals with
type 2 diabetes. Methods: In an open-label, parallel-group trial, metformin-trea-
ted participants were randomised to liraglutide 1.2 mg⁄day (n = 225), liraglutide
1.8 mg⁄day (n = 221) or sitagliptin 100 mg⁄day (n = 219) for 26 weeks (main
phase). Participants continued the same treatment in a 26-week extension.
Results: Liraglutide (1.2 or 1.8 mg) was superior to sitagliptin for reducing HbA1c
from baseline (8.4–8.5%) to 52 weeks: )1.29% and )1.51% vs. )0.88% respec-
tively. Estimated mean treatment differences between liraglutide and sitagliptin
were as follows: )0.40% (95% conﬁdence interval )0.59 to )0.22) for 1.2 mg
and )0.63% ()0.81 to )0.44) for 1.8 mg (both p < 0.0001). Weight loss was
greater with liraglutide 1.2 mg ()2.78 kg) and 1.8 mg ()3.68 kg) than sitagliptin
()1.16 kg) (both p < 0.0001). Diabetes Treatment Satisfaction Questionnaire
scores increased signiﬁcantly more with liraglutide 1.8 mg than with sitagliptin
(p = 0.03). Proportions of participants reporting adverse events were generally
comparable; minor hypoglycaemia was 8.1%, 8.3% and 6.4% for liraglutide
1.2 mg, 1.8 mg and sitagliptin respectively. Gastrointestinal side effects, mainly
nausea, initially occurred more frequently with liraglutide, but declined after several
weeks. Conclusion: Liraglutide provides greater sustained glycaemic control and
body weight reduction over 52 weeks. Treatment satisfaction was signiﬁcantly
greater with 1.8 mg liraglutide, similar to 26-week results. The safety proﬁles of
liraglutide and sitagliptin are consistent with previous reports.
What’s known
Results of independent trials and several 26-week
head-to-head trials suggest that GLP-1 receptor
agonists produce greater glycaemic and weight
reductions compared with DPP-4 inhibitors. Our
26-week trial showed that the human once-daily
GLP-1 analogue liraglutide effected greater
glycaemic control and weight loss than the DPP-4
inhibitor sitagliptin.
What’s new
Longer-term sustainability of the 26-week efﬁcacy
and safety results with liraglutide and sitagliptin, as
well as the maintenance of the greater comparative
efﬁcacy with liraglutide, was not known. This report
shows that 26-week improvements were sustained
after 52 weeks of treatment, with liraglutide
producing signiﬁcantly greater glycaemic and
weight reductions than sitagliptin.
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and do not produce weight gain (3–6). Glucagon-like
peptide-1 (GLP-1) receptor agonists and dipeptidyl
peptidase-4 (DPP-4) inhibitors are two distinct clas-
ses of incretin-based therapies. While 26-week, head-
to-head studies suggest that GLP-1 receptor agonists
have greater glycaemic and weight reduction efﬁcacy
than DPP-4 inhibitors (7–9), longer-term results
have not been reported.
In a 26-week, head-to-head trial of the once-daily
human GLP-1 analogue liraglutide and the DPP-4
inhibitor sitagliptin, both in combination with met-
formin, liraglutide (1.2 or 1.8 mg⁄day) was signiﬁ-
cantly more effective than sitagliptin (100 mg⁄day)
for reducing HbA1c ()1.24% and )1.50% vs. )0.90%
respectively), fasting plasma glucose (FPG)
()1.87 mmol⁄l[ )33.66 mg⁄dl] and )2.14 mmol⁄l
[)38.52 mg⁄dl] vs. )0.83 mmol⁄l[ )14.94 mg⁄dl],
respectively) and body weight ()2.86 and )3.38 kg
vs. )0.96 kg respectively) (8). Incidence of minor
hypoglycaemia was low (around 5%) and compara-
ble across treatment groups. Nausea incidence was
greater with liraglutide than with sitagliptin during
therapy initiation, but generally declined after several
weeks of treatment.
Trial participants could continue treatment in a
26-week extension phase designed to evaluate the
sustainability of efﬁcacy and safety effects of liraglu-
tide and sitagliptin. This report shows that 26-week
improvements were sustained after 52 weeks of treat-
ment, with liraglutide producing greater glycaemic
and weight reductions than sitagliptin.
Methods
Study design
Details of study design and participant inclu-
sion⁄exclusion criteria have been reported previously
(8). Brieﬂy, in a multinational, randomised, parallel-
group, open-label, active-comparator trial, participants
with T2D previously treated with metformin mono-
therapy (‡ 1500 mg⁄day) for a minimum of 3 months,
but with suboptimal glycaemic control (HbA1c 7.5–
10%), were randomised (1 : 1 : 1) to treatment with
either liraglutide 1.2 or 1.8 mg⁄day (subcutaneous
injection) or sitagliptin 100 mg⁄day (orally) while
continuing on existing metformin therapy.
After completing the 26-week main phase, partici-
pants choosing to enrol in the extension provided
written informed consent and continued for another
26 weeks in their originally assigned treatment
groups. The protocol, including the extension, was
institutional review board-approved, followed Good
Clinical Practice guidelines and conformed to the
Declaration of Helsinki. The 52-week trial was
initiated on 16 June 2008 and completed on 10
December 2009.
Additional withdrawal criteria during the exten-
sion were: elevated FPG > 11.1 mmol⁄l (200 mg⁄dl)
with no treatable intercurrent cause or acute pancre-
atitis (deﬁned as a minimum two out of three of the
following: characteristic abdominal pain, amylase
and⁄or lipase > 3 · upper normal range or charac-
teristic ﬁndings on computed tomography⁄magnetic
resonance imaging).
Outcomes
Efﬁcacy outcomes assessed at 52 weeks included
change in HbA1c, FPG, body weight, proportion of
participants achieving HbA1c <7 %o r£ 6.5%, pro-
portion of participants reaching the composite end-
point of HbA1c < 7.0% with no weight gain and no
conﬁrmed major (participant unable to treat
him⁄herself) or minor (plasma glucose < 3.1 mmol⁄l
[56 mg⁄dl]) hypoglycaemia. Other measures included
fasting C-peptide, fasting pro-insulin : insulin ratio,
and homeostasis model assessment analyses of beta-
cell function (HOMA-B) and insulin resistance
(HOMA-IR). Change in Diabetes Treatment Satisfac-
tion Questionnaire (DTSQ) scores from baseline was
not assessed in participants from Slovakia, Serbia or
Slovenia (118⁄665 [17.7%]) because of the lack of
validated questionnaires in their native languages.
Safety and tolerability assessments at 52 weeks
included incidence of adverse events (AEs) and hyp-
oglycaemia, as well as various clinical and laboratory
variables. AEs of special interest included nausea,
thyroid AEs and pancreatitis.
Statistical analysis
Methods for statistical analyses were similar to those
reported for the ﬁrst 26 weeks (8). Glycaemic efﬁ-
cacy, as measured by change in HbA1c from baseline
to week 52 of liraglutide vs. sitagliptin treatment,
was assessed by a non-inferiority comparison with a
margin of 0.4%, followed by a superiority compari-
son. Both tests used two-sided hypotheses, with a
p-value of < 0.05 considered signiﬁcant. Analysis of
covariance, with treatment and country as ﬁxed
effects and baseline measure as a covariate, was used
for continuous efﬁcacy end-points. Logistic regres-
sion was used to analyse categorical variables, includ-
ing the participant proportions achieving HbA1c
targets and composite end-point (HbA1c < 7.0% with
no weight gain and no conﬁrmed major or minor
hypoglycaemia), with treatment and country as ﬁxed
effects, and baseline HbA1c (and body weight for
composite) as covariates. Efﬁcacy assessments were
performed on the full analysis set: all randomised
participants exposed to at least one dose of the drug.
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carried forward (LOCF) method.
The safety analysis set included all participants
exposed to at least one dose of the drug they were
randomised to. Serum calcitonin values were analy-
sed using a repeated measures model, with time,
gender, treatment and treatment-by-time interaction
as ﬁxed effects and participant as a random effect.
Hypoglycaemia was analysed using a general linear
model with treatment as a ﬁxed effect. For each
week of the extension, the proportions of partici-
pants experiencing nausea were analysed using Fish-
er’s exact test. Only summary statistics are reported
for other safety parameters. Data are reported as
least square means with 95% conﬁdence interval
(CI), unless otherwise noted. The signiﬁcance level
is p < 0.05.
Results
Participant disposition and baseline
characteristics
After screening, 665 participants were randomised
into three treatment arms: liraglutide 1.2 mg, 1.8 mg
and sitagliptin (Figure 1). As previously reported, the
groups were well matched for baseline characteristics
(8). Of participants completing 26 weeks, 497⁄554
(90%) entered into the extension, with 436⁄497
(88%) completing 52 weeks. A lower proportion of
randomised participants withdrew from the exten-
sion compared with the main phase, and withdrawal
because of AEs was also lower in the extension.
Patient withdrawal because of AEs in the main phase
was higher for both liraglutide groups than for sitag-
liptin, whereas only the liraglutide 1.8 mg group had
a slightly higher AE withdrawal rate in the extension.
Efﬁcacy outcomes
Mean HbA1c decreased more substantially with either
dose of liraglutide compared with sitagliptin during
the ﬁrst 12 weeks, and these reductions were gener-
ally maintained up to week 52 (Figure 2A). Mean
reductions in HbA1c from baseline to week 52 with
liraglutide 1.2 mg ()1.29% [95% CI: )1.43 to
)1.15]) and 1.8 mg ()1.51% [)1.65 to )1.37]) were
signiﬁcantly greater compared with sitagliptin
()0.88% [)1.02 to )0.74]). Estimated mean treat-
ment differences were )0.40% (95% CI )0.59 to
)0.22) for liraglutide 1.2 mg vs. sitagliptin and
)0.63% ()0.81 to )0.44) for liraglutide 1.8 mg vs.
sitagliptin (p < 0.0001 for both doses.)
As with HbA1c, liraglutide was more effective for
reducing FPG compared with sitagliptin (Figure 2B).
FPG declined rapidly from baseline during weeks 0–4
in all treatment groups and the reductions were gen-
erally sustained up to 52 weeks. FPG reductions from
baseline at week 52 were )1.71 mmol⁄l (95% CI
)2.04 to )1.38) ()30.78 mg⁄dl [)36.78 to )24.78])
for 1.2 mg liraglutide and )2.04 mmol⁄l( )2.37 to
)1.71) ()36.72 mg⁄dl [)42.72 to )30.72]) for
1.8 mg liraglutide vs. )0.59 mmol⁄l( )0.92 to )0.26)
()10.62 mg⁄dl [)16.62 to )4.62]) for sitagliptin.
Estimated mean treatment differences between lira-
glutide and sitagliptin were )1.13 mmol⁄l (95% CI
)1.57 to )0.68) ()20.34 mg⁄dl [)28.26 to )12.24])
for 1.2 mg and )1.45 mmol⁄l( )1.89 to )1.01)
()26.1 mg⁄dl [)34.02 to )18.18]) for 1.8 mg
(p < 0.0001 vs. sitagliptin for both doses).
Weight loss was considerably greater with liraglu-
tide compared with sitagliptin (Figure 2C). Most
weight loss occurred during the ﬁrst 26 weeks and
was sustained in the extension in all treatment
groups (Figure 2C). At week 52, weight loss with
liraglutide 1.2 mg was )2.78 kg (95% CI )3.39 to
)2.17) compared with )3.68 kg ()4.29 to )3.07) for
1.8 mg and )1.16 kg ()1.77 to )0.55) for sitagliptin.
Estimated mean treatment differences were )1.62 kg
(95% CI )2.43 to )0.82) for liraglutide 1.2 mg and
)2.53 kg ()3.33 to )1.72) for liraglutide 1.8 mg vs.
sitagliptin (p < 0.0001 for both doses). Weight loss
with liraglutide 1.8 mg was signiﬁcantly greater than
that with liraglutide 1.2 mg (p = 0.03). The 26-week-
reductions in waist circumference were generally
maintained at week 52 in all groups and were signiﬁ-
cantly larger with liraglutide (both doses) than sitag-
liptin (Table 1).
As with the main study results (8), postprandial
plasma glucose data were highly variable and difﬁcult
to interpret, and are excluded from this report. As
this was a multinational study, data variability may
have resulted from the varying meal content, time of
meals and timing of postprandial glucose measure-
ments across different countries.
Overall, the magnitude of HbA1c reduction from
baseline increased with the higher baseline HbA1c
categories in all groups (Figure 3A). After 52 weeks,
mean reductions in HbA1c were signiﬁcantly greater
with liraglutide 1.8 mg than with sitagliptin across all
baseline HbA1c categories. The reductions were sig-
niﬁcantly larger with liraglutide 1.2 mg than with
sitagliptin for two baseline HbA1c categories: > 8%
to £ 8.5% and > 9%.
Proportions of participants achieving target HbA1c
< 7% (American Diabetes Association [ADA] target)
or £ 6.5% (American Association of Clinical Endo-
crinologists [AACE] target) increased during the
extension in all treatment groups (Figure 3B). Over-
all, liraglutide (both doses) was signiﬁcantly more
effective than sitagliptin in allowing patients to reach
target HbA1c after 52 weeks.
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the composite end-point of HbA1c < 7.0%, with
no weight gain and no conﬁrmed major or minor
hypoglycaemia, increased during the extension in all
treatment groups (Figure 3C). After 52 weeks, a sig-
niﬁcantly greater percentage of participants achieved
the composite end-point with liraglutide (both
groups) than with sitagliptin, with an odds ratio
(OR) vs. sitagliptin of 2.80 (95% CI 1.74 to 4.48)
and 4.37 (2.74 to 6.98) for 1.2 and 1.8 mg liraglutide
respectively (both doses p < 0.0001). Liraglutide
1.8 mg was more effective than liraglutide 1.2 mg
(OR: 1.56 [1.04 to 2.35], p = 0.03).
Overall, the improved status of several indicators
of beta-cell function (fasting C-peptide, fasting pro-
insulin:insulin ratio and HOMA-B) at week 26 was
maintained at week 52, with liraglutide effecting
signiﬁcantly greater improvements than sitagliptin
(Table 1). The reduction in HOMA-IR became sig-
niﬁcantly greater with liraglutide 1.8 mg than sitag-
liptin during the extension. As observed at week 26,
mean heart rate continued to be slightly but signiﬁ-
Figure 1 Trial ﬂow chart with participant demographics at baseline. Demographic data are mean ± SD, unless otherwise
noted. *Participants were withdrawn if they fulﬁlled withdrawal criteria, decided that they no longer wanted to participate,
or did not attend any visit after randomisation. BMI, body mass index; FAS, full analysis set; FPG, fasting plasma glucose
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liptin at week 52 (Table 1).
The increase in DTSQ scores at week 26 was gen-
erally sustained at week 52 in all treatment groups.
The improvement in overall treatment satisfaction,
measured as the increase in DTSQ scores between
weeks 0 and 52, was signiﬁcantly higher with liraglu-
tide 1.8 mg (baseline: 28.0) than with sitagliptin
(baseline: 27.1): 4.3 (95% CI 3.3 to 5.3) vs. 3.0 (2.0
to 4.0) (p = 0.03). By contrast, the increase from
baseline (27.8) with liraglutide 1.2 mg (3.3 [2.3 to
4.3]) was not statistically different from sitagliptin.
Safety outcomes
The majority (‡ 97%) of treatment-emergent AEs in
all groups over 52 weeks were mild or moderate. The
proportion of participants reporting serious AEs was
low and comparable between treatment groups
(4.5%, 6.0% and 5.5% for liraglutide 1.2 mg, 1.8 mg
and sitagliptin respectively) with no consistent
pattern with respect to system organ class (Table 2).
Three deaths occurred during the 52-week period.
Two deaths during the ﬁrst 26 weeks, one in a
participant with pancreatic carcinoma (liraglutide
1.8 mg) and one because of cardiac arrest (sitaglip-
tin), were reported previously and considered unli-
kely to be related to the trial drugs (8). One sudden
cardiac death during the extension occurred in a 66-
year-old man randomised to sitagliptin and was
judged as unlikely to be related to the trial drug by
the investigator.
Gastrointestinal disorders, as well as infections and
infestations, were the most commonly reported mild-
to-moderate AEs with liraglutide. The incidence
of nausea, the most prevalent gastrointestinal AE
with liraglutide, declined after the ﬁrst 3 weeks of
treatment and remained low during the extension
(Figure 4). For each week of the extension, the pro-
portions of participants experiencing nausea did not
differ signiﬁcantly between liraglutide (1.2 or 1.8 mg)
and sitagliptin treatment groups.
One episode of major hypoglycaemia (blood glu-
cose 3.6 mmol⁄l [64.8 mg⁄dl]) occurred during the
ﬁrst 26 weeks in a participant on liraglutide 1.2 mg
(8). Third-party assistance was required, but no sei-
zures or coma occurred. The participant recovered
and the episode was categorised as possibly related to
the trial product by the investigator. No major hypo-
glycaemic episodes occurred during the extension.
Minor hypoglycaemia rates were low and comparable
between treatment groups over 52 weeks, after
excluding an outlier in the 1.8 mg liraglutide group
with 21 minor events during the ﬁrst 26 weeks and
two events in the extension (leading to participant
withdrawal from the trial). Adjusted minor hypo-
glycaemia rates were 0.143, 0.154 and 0.137 hypogly-
caemic episodes per patient per year for liraglutide
1.2 mg, 1.8 mg and sitagliptin respectively.
One case of ‘non-acute’ pancreatitis was reported
during the extension in a 54-year-old man, with a
medical history of hepatitis and hyperlipidaemia,
treated with liraglutide 1.8 mg for 227 days. Initially,
the participant experienced abdominal pain, nausea,
vomiting for 1 day and black stools for 3 days. The
participant was instructed to stop aspirin and initiate
omeprazole treatment. Upon later hospitalisation for
a different condition, laboratory tests showed slightly
increased levels of amylase (2.6 lkat⁄l, normal range:
0–1.67 lkat⁄l) and lipase (1.44 lkat⁄l, normal range:
0–1 lkat⁄l). The investigator decided to withdraw
the participant, although the speciﬁc withdrawal cri-
teria for acute pancreatitis were not met. The event
was rated as mild and possibly related to the trial
drug by the investigator.
Figure 2 Effect of 1.2 mg liraglutide, 1.8 mg liraglutide or
100 mg sitagliptin on glycaemic control and body weight
from baseline to 52 weeks. (A) Mean HbA1c values. (B)
Mean fasting plasma glucose (FPG) values. (C) Mean
change in body weight. Error bars are 1.96 · SE,
corresponding to the 95% CI
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of C-cell hyperplasia, were small and there were no
statistically signiﬁcant differences between treatment
groups. Mean calcitonin levels remained below the
upper normal limit for both genders from baseline
to 52 weeks. The proportions of subjects reporting
thyroid-related treatment-emergent AEs were compa-
rable across treatment groups (5.0%, 5.5% and 4.6%
for liraglutide 1.2 mg, 1.8 mg and sitagliptin respec-
tively) (Table S1). No cases of thyroid malignancy
were found during the trial period (Table S2).
Discussion
Liraglutide produced sustained and greater reduc-
tions in HbA1c, FPG and body weight compared
with sitagliptin after 52 weeks of treatment, similar
to results previously reported after week 26 (8).
Figure 3 Mean reductions in HbA1c by baseline category and proportions of participants reaching target end-points with
1.2 mg liraglutide, 1.8 mg liraglutide and 100 mg sitagliptin from weeks 0–52. (A) Mean reductions in HbA1c from
baseline to week 52 by baseline HbA1c category. (B) Percentage of participants achieving target HbA1c < 7% (ADA) or
£ 6.5% (AACE). (C) Percentage of participants reaching the composite end-point of HbA1c < 7.0%, with no weight gain
and no conﬁrmed major or minor hypoglycaemia. In (B) and (C), solid bar portions represent percentages from weeks
0–26, while shaded portions represent percentages from weeks 27–52. *p < 0.05 vs. sitagliptin; **p £ 0.01 vs. sitagliptin;
***p < 0.001 vs. sitagliptin. p-values are derived from a logistic regression model with treatment and country as ﬁxed
effects and baseline HbA1c and body weight (for composite) as covariate(s). AACE, American Association of Clinical
Endocrinologists; ADA, American Diabetes Association
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ª 2011 Blackwell Publishing Ltd Int J Clin Pract, April 2011, 65, 4, 397–407Furthermore, liraglutide improved glycaemic control
to a greater extent than sitagliptin irrespective of
baseline HbA1c values, although with a higher fre-
quency of gastrointestinal side effects during the ﬁrst
few weeks of treatment.
The greater glycaemic efﬁcacy with liraglutide may
derive from the different mechanism of action of
GLP-1 receptor agonists and DPP-4 inhibitors.
GLP-1 receptor agonists achieve greater (pharmaco-
logical) levels of GLP-1 activity, which, together with
the extended half-life of liraglutide (13 h), results in
effective, 24-h glucose control with once-daily dosing
(10,11), as evidenced by the greater reductions in
FPG. By contrast, DPP-4 inhibitors indirectly modu-
late endogenous GLP-1 and glucose-dependent insu-
linotropic polypeptide (GIP) concentrations by
inhibiting the degradation of these peptide hormones
by DPP-4. However, because individuals with T2D
are resistant to GIP, endogenous GLP-1 may be
insufﬁcient for effective glycaemic control, which
may partially explain the lower efﬁcacy with DPP-4
inhibitors (12).
Greater weight reduction with liraglutide com-
pared with sitagliptin can also be attributed to the
mechanistic differences of GLP-1 analogues and
DPP-4 inhibitors. Previous studies have shown that
GLP-1 receptor agonists increase satiety, reduce food
intake and promote weight loss (13,14), whereas
DPP-4 inhibitors are generally weight-neutral (3).
Our efﬁcacy ﬁndings over 52 weeks are supported
by the results of other shorter head-to-head trials,
where exenatide once weekly (DURATION-2) or
taspoglutide (T-emerge 4) were compared with sitag-
liptin over 26 weeks (7,9). In these trials, HbA1c was
reduced by 1.5% and 1.3% with exenatide once weekly
and taspoglutide, respectively, vs. 0.9% with sitagliptin.
Thus, the overall efﬁcacy results for sitagliptin in our
trial are comparable, and for body weight change, even
better, than the results of other trials that have gener-
ally shown DPP-4 inhibitors to be weight-neutral.
Trials investigating the ability of incretin-based
therapies to provide early and sustained glycaemic
management are important in light of recent ﬁndings
that periods of poorly controlled hyperglycaemia
increased future risk of diabetes-related death and
complications (15–17). Our trial showed that liraglu-
tide treatment initiation produced early and effective
glycaemic control, as evidenced by HbA1c £ 7% by
week 12 and FPG 7.7–7.8 mmol⁄l (138.6–
140.4 mg⁄dl) by week 4, and this control was gener-
ally maintained up to 52 weeks.
According to the ADA’s latest Standards of Care,
diabetes treatment needs to move beyond a gluco-
centric approach that focuses solely on controlling
Table 2 Participants with treatment-emergent adverse events during weeks 0–52
Adverse events
Liraglutide
1.2 mg/day
(n = 221)
Liraglutide
1.8 mg/day
(n = 218)
Sitagliptin
100 mg/day
(n = 219)
Serious adverse events* 10 (4.5) 13 (6.0) 12 (5.5)
Deaths 0 1 (0.5) 2 (0.9)
Severe adverse events 12 (5.4) 15 (6.9) 13 (5.9)
Gastrointestinal disorders 4 (1.8) 5 (2.3) 4 (1Æ8)
Musculoskeletal and connective
tissue disorders
3 (1.4) 1 (0.5) 1 (0.5)
Infections and infestations 3 (1.4) 3 (1.4) 3 (1.4)
Neoplasms (benign, malignant
and unspeciﬁed)
1 (0.5) 3 (1.4) 1 (0.5)
Cardiac disorders 2 (0.9) 1 (0.5) 1 (0.5)
Investigations 0 (0.0) 1 (0.5) 0 (0.0)
Nervous system disorders 0 (0.0) 0 (0.0) 2 (0.9)
Renal and urinary disorders 0 (0.0) 0 (0.0) 1 (0.5)
Adverse events (of any severity)
reported by > 5% of participants
158 (71.5) 167 (76.6) 139 (63.5)
Gastrointestinal disorders 80 (36.2) 94 (43.1) 52 (23.7)
Nausea 48 (21.7) 60 (27.5) 12 (5.5)
Vomiting 18 (8.1) 23 (10.6) 11 (5.0)
Diarrhoea 20 (9.0) 27 (12.4) 14 (6.4)
Constipation 10 (4.5) 13 (6.0) 8 (3.7)
Dyspepsia 8 (3.6) 15 (6.9) 5 (2.3)
Infections and infestations 74 (33.5) 77 (35.3) 75 (34.2)
Nasopharyngitis 27 (12.2) 32 (14.7) 31 (14.2)
Inﬂuenza 13 (5.9) 4 (1.8) 8 (3.7)
Nervous system disorders 40 (18.1) 48 (22.0) 44 (20.1)
Headache 21 (9.5) 29 (13.3) 27 (12.3)
Musculoskeletal and connective
tissue disorders
39 (17.6) 45 (20.6) 45 (20.5)
General disorders and administration-site
conditions
31 (14.0) 32 (14.7) 13 (5.9)
Metabolism and nutrition disorders 25 (11.3) 27 (12.4) 19 (8.7)
Decreased appetite 8 (3.6) 12 (5.5) 3 (1.4)
Investigations 21 (9.5) 27 (12.4) 16 (7.3)
Skin and subcutaneous tissue disorders 22 (10.0) 20 (9.2) 22 (10.0)
Respiratory, thoracic and mediastinal
disorders
16 (7.2) 18 (8.3) 21 (9.6)
Injury, poisoning and procedural
complications
20 (9.0) 20 (9.2) 21 (9.6)
Vascular disorders 16 (7.2) 15 (6.9) 10 (4.6)
Data are number (%) of participants. A participant could experience more than one adverse
event. *Liraglutide 1.2 mg group: acute myocardial infarction, myocardial infarction, epiglottic
carcinoma, thyroid disorder, hypertensive crisis (relapsing), hypoesthesia, coxarthrosis defor-
mans, worsening of coxarthrosis, haemorrhagic anaemia, haematochezia, infected sebaceous
cyst; liraglutide 1.8 mg group: pancreatic carcinoma (fatal), renal adenoma, breast cancer,
colon cancer, heart failure, sepsis, chest discomfort, subdural haematoma, subileus, pneumo-
nia, diabetic retinopathy and papilloedema, mycotic mycetoma of left sphenoidal sinus and
epistaxis, right hip arthroplasty, cholecystitis, peritonitis, worsening of cervicocranial syn-
drome; sitagliptin group: cardiac arrest (fatal), sudden cardiac death (fatal), renal carcinoma,
colonic polyp, postmenopausal vaginal haemorrhage and leiomyoma, worsening morbus
Osler, worsening of sleep apnoea; right meniscus rupture, anal abscess, hernia inguinalis (left
side), acute cholecystitis, dengue fever.
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(18). Optimised therapies should also address the
comorbidities frequently associated with diabetes (i.e.
obesity, hypertension and dyslipidaemia). Based on
this multifactorial approach, we showed that, with
liraglutide 1.8 mg, 50% of participants achieved
HbA1c < 7% with concomitant weight loss and mini-
mal risk of hypoglycaemia, whereas only 19% of par-
ticipants on sitagliptin were able to meet these
criteria. While liraglutide did not signiﬁcantly reduce
systolic blood pressure compared with sitagliptin, the
decrease in the 1.8 mg group was consistent with
results of the LEAD-1 and LEAD-2 trials ()2.8 and
)2.3 mmHg respectively) (11,19). The signiﬁcant
improvement in beta-cell function with liraglutide
probably relates to reduced glucose toxicity because
of improved glycaemic control and⁄or a direct effect
on beta-cells, as has been shown in animal models
with GLP-1 (20,21). The reduction in insulin resis-
tance (HOMA-IR) from baseline with 1.8 mg liraglu-
tide in our study ()1.36%) was similar to that in the
52-week LEAD-3 trial ()1.35%) (22), and may be
related to body weight reduction. Overall, greater
improvements were observed with 1.8 mg than
1.2 mg liraglutide after 52 weeks. The 1.2 mg dose
did not decrease systolic blood pressure, did not sig-
niﬁcantly improve fasting C-peptide concentration or
insulin resistance and enabled only 39% of patients
to reach the abovementioned composite end-point.
Patient acceptance is a crucial element of treat-
ment success. Although both doses of injectable lira-
glutide produced similar improvements in overall
treatment satisfaction scores, only the improvement
in the 1.8 mg group reached statistical signiﬁcance
compared with oral sitagliptin, similar to results at
26 weeks. The higher overall treatment satisfaction
with liraglutide 1.8 mg vs. sitagliptin after 52 weeks
may be attributed, in part, to the greater glycaemic
and weight beneﬁts of liraglutide, along with good
tolerability and availability in a simple injection
device. Greater treatment satisfaction with injectable
GLP-1 therapy over oral DPP-4 therapy is consistent
with ﬁndings from another trial (9). Patient satisfac-
tion with treatment is important because it may offer
a clinically valuable indication on treatment adher-
ence (23), and relates to long-term outcomes.
In agreement with previous ﬁndings, both drugs
were generally safe and well tolerated (24–26). Nau-
sea was higher with liraglutide than with sitagliptin,
most probably because of the greater (pharmacologi-
cal) levels of GLP-1 activity. The decline in nausea
incidence after the ﬁrst 3 weeks is consistent with the
transient nature of nausea upon initiation of GLP-1
therapy (24).
A small increase in heart rate (2–3 beats⁄min)
occurred with liraglutide in this trial, similar to the
2–4 beats⁄min increases reported in previous studies
(11,19,22,27,28). The clinical signiﬁcance of this ele-
vation is not clear, but a similar increase (2 beats⁄
min) was reported with another GLP-1 receptor ago-
nist, exenatide twice daily (29). Calcitonin and thy-
roid AEs were recorded because of potential
concerns that originated in preclinical testing with
GLP-1 receptor agonists. Consistent with previous
clinical trials with liraglutide, calcitonin levels
remained well below the upper limit of normal for
Figure 4 Weekly percentage of participants reporting nausea with 1.2 mg liraglutide, 1.8 mg liraglutide or 100 mg
sitagliptin during weeks 0–52. Weekly proportions of participants experiencing nausea during the extension (weeks 27–52)
did not differ signiﬁcantly between liraglutide (1.2 or 1.8 mg) and sitagliptin treatment groups
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roid events were reported by few trial participants
and the proportions of participants with these events
were comparable between liraglutide (1.2 or 1.8 mg)
and sitagliptin groups. No cases of thyroid cancer
were reported.
Our study design had some limitations, includ-
ing the absence of a placebo group to serve as a
benchmark for some of the safety end-points and
the lack of double-blinding. In addition, LOCF
imputation of the 26-week data may have resulted
in a conservative estimate of the 52-week effect of
the study drugs. However, statistical analyses of the
HbA1c and body weight end-points performed
using a completers analysis set produced similar
results. LOCF is a commonly used method for
imputing missing data and is transparent in the
context of diabetes trials (30).
GLP-1 receptor agonists are given preference over
DPP-4 inhibitors in dual- and triple-therapy intensi-
ﬁcation regimens after metformin by the AACE and
by the ADA⁄European Association for the Study of
Diabetes as a tier-2 therapy when hypoglycaemia and
weight concerns are paramount (1,2). However, these
guidelines do not mention liraglutide, as it was not
approved at the time of publication. Furthermore,
the current treatment algorithms are mostly based on
the results of independent trials with either GLP-1
receptor agonists or DPP-4 inhibitors against other
agents or placebo. Our trial offers the ﬁrst 52-week,
direct comparison of the overall clinical proﬁles of
the two types of incretin therapy, and provides sup-
port for the use of GLP-1 receptor agonists as an
efﬁcacious alternative to DPP-4 inhibitors in treat-
ment intensiﬁcation algorithms.
In summary, 52 weeks of liraglutide treatment in
combination with metformin provides sustained and
superior glycaemic control and signiﬁcant body
weight reduction compared with sitagliptin in com-
bination with metformin, while maintaining a com-
parable safety and tolerability proﬁle, albeit with
more gastrointestinal side effects initially, in partici-
pants with T2D.
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